AIRLINK 198.72 Increased By ▲ 0.75 (0.38%)
BOP 10.03 Decreased By ▼ -0.01 (-0.1%)
CNERGY 7.30 Increased By ▲ 0.01 (0.14%)
FCCL 36.51 Increased By ▲ 0.51 (1.42%)
FFL 17.00 Increased By ▲ 0.09 (0.53%)
FLYNG 25.50 Increased By ▲ 0.46 (1.84%)
HUBC 135.50 Increased By ▲ 1.47 (1.1%)
HUMNL 14.05 Decreased By ▼ -0.09 (-0.64%)
KEL 4.78 No Change ▼ 0.00 (0%)
KOSM 6.91 Decreased By ▼ -0.03 (-0.43%)
MLCF 45.35 Increased By ▲ 0.37 (0.82%)
OGDC 218.70 Increased By ▲ 0.47 (0.22%)
PACE 6.94 No Change ▼ 0.00 (0%)
PAEL 41.40 Decreased By ▼ -0.02 (-0.05%)
PIAHCLA 16.87 Increased By ▲ 0.01 (0.06%)
PIBTL 8.45 Decreased By ▼ -0.01 (-0.12%)
POWER 9.54 Increased By ▲ 0.15 (1.6%)
PPL 184.97 Decreased By ▼ -0.96 (-0.52%)
PRL 41.25 Decreased By ▼ -0.02 (-0.05%)
PTC 25.10 Increased By ▲ 0.33 (1.33%)
SEARL 103.80 Decreased By ▼ -0.85 (-0.81%)
SILK 1.03 Increased By ▲ 0.02 (1.98%)
SSGC 40.45 Decreased By ▼ -0.46 (-1.12%)
SYM 17.88 Decreased By ▼ -0.17 (-0.94%)
TELE 8.94 Increased By ▲ 0.03 (0.34%)
TPLP 12.80 Decreased By ▼ -0.04 (-0.31%)
TRG 67.25 Increased By ▲ 0.65 (0.98%)
WAVESAPP 11.42 Increased By ▲ 0.12 (1.06%)
WTL 1.79 Increased By ▲ 0.01 (0.56%)
YOUW 4.00 No Change ▼ 0.00 (0%)
BR100 12,091 Decreased By -18.8 (-0.16%)
BR30 36,578 Decreased By -19.7 (-0.05%)
KSE100 115,181 Increased By 138.7 (0.12%)
KSE30 36,225 Increased By 25.6 (0.07%)

WASHINGTON: The US Centers for Disease Control and Prevention (CDC) on Thursday recommended Covid-19 booster shots from Pfizer and Moderna targeting the Omicron variant, clearing the way for the administration of the shots.

This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States.

The Pfizer-BioNTech shot is recommended for people 12 and older and Moderna’s for those 18 years and up.

“The updated Covid-19 boosters are formulated to better protect against the most recently circulating Covid-19 variant. They can help restore protection that has waned since previous vaccination and were designed to provide broader protection against newer variants,” CDC Director Rochelle Walensky said in a statement.

“This recommendation followed a comprehensive scientific evaluation and robust scientific discussion,” she added.

COVID drives down US life expectancy for the second straight year

The new versions of the vaccines – which were approved by the US Food and Drug Administration on Wednesday – could potentially be available in the United States as early as next week.

The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.

In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.

Comments

Comments are closed.